These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36070008)

  • 1. Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.
    De Masi C; Liguori C; Spanetta M; Fernandes M; Cerroni R; Garasto E; Pierantozzi M; Mercuri NB; Stefani A
    J Neural Transm (Vienna); 2022 Nov; 129(11):1331-1338. PubMed ID: 36070008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
    Grigoriou S; Martínez-Martín P; Ray Chaudhuri K; Rukavina K; Leta V; Hausbrand D; Falkenburger B; Odin P; Reichmann H
    Brain Behav; 2021 Oct; 11(10):e2336. PubMed ID: 34478245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
    De Micco R; Satolli S; Siciliano M; De Mase A; Giordano A; Tedeschi G; Tessitore A
    Neurol Sci; 2022 Jan; 43(1):357-364. PubMed ID: 34031800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatigue in fluctuating Parkinson's disease patients: possible impact of safinamide.
    Pauletti C; Locuratolo N; Mannarelli D; Maffucci A; Petritis A; Menini E; Fattapposta F
    J Neural Transm (Vienna); 2023 Jul; 130(7):915-923. PubMed ID: 37210459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study.
    Santos García D; Cabo López I; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Paz González JM; Alonso Losada MG; Gonzalez Palmás MJ; Cores Bartolomé C; Martínez Miró C
    Neurol Sci; 2022 Apr; 43(4):2537-2544. PubMed ID: 34554335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.
    Cattaneo C; Barone P; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2017; 7(1):95-101. PubMed ID: 27802242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
    Rizzone MG; Mancini F; Artusi CA; Balestrino R; Bonvegna S; Fabbri M; Imbalzano G; Montanaro E; Romagnolo A; Zibetti M; Lopiano L
    Neurol Sci; 2022 May; 43(5):3187-3193. PubMed ID: 34982297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
    Bianchi MLE; Riboldazzi G; Mauri M; Versino M
    Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study.
    Geroin C; Di Vico IA; Squintani G; Segatti A; Bovi T; Tinazzi M
    J Neural Transm (Vienna); 2020 Aug; 127(8):1143-1152. PubMed ID: 32572581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
    Santos García D; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz Gonález JM; Alonso Losada MG; González Palmás MJ; Martínez Miró C
    Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33801565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
    Labandeira CM; Alonso Losada MG; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz González JM; Gonzalez Palmás MJ; Martínez Miró C; Santos García D
    Adv Ther; 2021 Oct; 38(10):5398-5411. PubMed ID: 34523075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.
    Bovenzi R; Liguori C; Canesi M; D'Amelio M; De Pandis MF; Marini C; Monge A; Padovani A; Tessitore A; Stefani A; Zappia M;
    Neurol Sci; 2024 Feb; 45(2):573-583. PubMed ID: 37684511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
    Liguori C; Stefani A; Ruffini R; Mercuri NB; Pierantozzi M
    Parkinsonism Relat Disord; 2018 Dec; 57():80-81. PubMed ID: 30006034
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.
    Espinoza-Vinces C; Villino-Rodríguez R; Atorrasagasti-Villar A; Martí-Andrés G; Luquin MR
    Patient Relat Outcome Meas; 2023; 14():285-295. PubMed ID: 37840836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study.
    Prakash KM; Nadkarni NV; Lye WK; Yong MH; Tan EK
    Eur J Neurol; 2016 May; 23(5):854-60. PubMed ID: 26806538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease and REM sleep behavior disorder result in increased non-motor symptoms.
    Neikrug AB; Avanzino JA; Liu L; Maglione JE; Natarajan L; Corey-Bloom J; Palmer BW; Loredo JS; Ancoli-Israel S
    Sleep Med; 2014 Aug; 15(8):959-66. PubMed ID: 24938585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
    Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
    Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
    Nomoto M; Ishida T; Koebis M; Kamei T; Suzuki I; Hattori N; Tsuboi Y
    J Neurol Sci; 2022 Mar; 434():120083. PubMed ID: 35007919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.